Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-Adhoc: Changes in the Management Board of Eckert & Ziegler
EQS-Adhoc: Changes in the Management Board of Eckert & Ziegler
EQS-Adhoc: Changes in the Management Board of Eckert & Ziegler
eqs_en 
0 19.12.22
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
eqs_en 
0 25.11.22
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
eqs_en 
0 25.11.22
EQS-News: ​​​​​​​Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
EQS-News: ​​​​​​​Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
EQS-News: ​​​​​​​Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
eqs_en 
0 08.11.22
EQS-News: ​​​​​​​Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
EQS-News: ​​​​​​​Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
EQS-News: ​​​​​​​Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
eqs_en 
0 08.11.22
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
eqs_en 
0 27.10.22
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
EQS-News: First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2 Trial
eqs_en 
0 27.10.22
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen


Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded

BusinessWire_EN 
0 17.10.22
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
eqs_en 
0 13.10.22
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
EQS-News: Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement
eqs_en 
0 13.10.22
EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
eqs_en 
0 11.10.22
EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
EQS-News: Eckert & Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility
eqs_en 
0 11.10.22
DGAP-News: ​​​​​​​Eckert & Ziegler with Successful First Half of 2022
DGAP-News: ​​​​​​​Eckert & Ziegler with Successful First Half of 2022
DGAP-News: ​​​​​​​Eckert & Ziegler with Successful First Half of 2022
eqs_en 
0 11.08.22
DGAP-News: ​​​​​​​Eckert & Ziegler with Successful First Half of 2022
DGAP-News: ​​​​​​​Eckert & Ziegler with Successful First Half of 2022
DGAP-News: ​​​​​​​Eckert & Ziegler with Successful First Half of 2022
eqs_en 
0 11.08.22
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
eqs_en 
0 04.08.22
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures
eqs_en 
0 04.08.22
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
eqs_en 
0 27.07.22
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
eqs_en 
0 27.07.22
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
eqs_en 
0 21.07.22
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development
eqs_en 
0 21.07.22
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
eqs_en 
0 20.07.22
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)
eqs_en 
0 20.07.22
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
eqs_en 
0 06.07.22
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
eqs_en 
0 06.07.22
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
eqs_en 
0 05.07.22